The U.S. Food and Drug Administration (FDA) on July 16 issued a warning for Proglycem (diazoxide) after reports of pulmonary hypertension in infants and newborns treated with the drug for low blood sugar. The FDA reports that the pulmonary hypertension improved after Proglycem was stopped. The agency urges health care professionals to closely monitor infants and newborns being treated with the drug and stop treatment if pulmonary hypertension occurs.

Read the FDA announcement.

Keywords: Blood Glucose, Diazoxide, Hypertension, Pulmonary, Hypoglycemia, Infant, Infant, Newborn, United States Food and Drug Administration, Heart Defects, Congenital

< Back to Listings